These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1279 related articles for article (PubMed ID: 20427088)

  • 41. Diabetic macular edema.
    Kim SJ
    Ophthalmology; 2009 Jun; 116(6):1228.e1; author reply 1228-9. PubMed ID: 19486803
    [No Abstract]   [Full Text] [Related]  

  • 42. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
    Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
    Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diabetic macular edema.
    Narula R; Agarwal M; Chaudhary SP; Shroff C
    Ophthalmology; 2009 Sep; 116(9):1833-4; author reply 1834. PubMed ID: 19729104
    [No Abstract]   [Full Text] [Related]  

  • 44. Intravitreal triamcinolone for refractory diabetic macular edema.
    Martidis A; Duker JS; Greenberg PB; Rogers AH; Puliafito CA; Reichel E; Baumal C
    Ophthalmology; 2002 May; 109(5):920-7. PubMed ID: 11986098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema.
    Kang SW; Sa HS; Cho HY; Kim JI
    Arch Ophthalmol; 2006 May; 124(5):653-8. PubMed ID: 16682586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
    Bressler NM; Edwards AR; Beck RW; Flaxel CJ; Glassman AR; Ip MS; Kollman C; Kuppermann BD; Stone TW;
    Arch Ophthalmol; 2009 Dec; 127(12):1566-71. PubMed ID: 20008708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial macular thickness and response to treatment in diabetic macular edema.
    Soheilian M; Ramezani A; Yaseri M; Mirdehghan SA; Obudi A; Bijanzadeh B
    Retina; 2011 Sep; 31(8):1564-73. PubMed ID: 21451442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.
    Nguyen QD; Shah SM; Heier JS; Do DV; Lim J; Boyer D; Abraham P; Campochiaro PA;
    Ophthalmology; 2009 Nov; 116(11):2175-81.e1. PubMed ID: 19700194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment.
    Patelli F; Fasolino G; Radice P; Russo S; Zumbo G; DI Tizio FM; Frisone G; Marchi S
    Retina; 2005; 25(7):840-5. PubMed ID: 16205561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema.
    Kang SW; Park SC; Cho HY; Kang JH
    Am J Ophthalmol; 2007 Dec; 144(6):878-885. PubMed ID: 17936715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
    Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
    Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U; Lang GE; Holz FG; Schlingemann RO; Lanzetta P; Massin P; Gerstner O; Bouazza AS; Shen H; Osborne A; Mitchell P;
    Ophthalmology; 2014 May; 121(5):1045-53. PubMed ID: 24491642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.
    Aiello LP; Edwards AR; Beck RW; Bressler NM; Davis MD; Ferris F; Glassman AR; Ip MS; Miller KM;
    Ophthalmology; 2010 May; 117(5):946-53. PubMed ID: 20122739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diode laser, vitrectomy and intravitreal triamcinolone. A comparative study for the treatment of diffuse non tractional diabetic macular edema.
    Parolini B; Panozzo G; Gusson E; Pinackatt S; Bertoldo G; Rottini S; Pignatto S
    Semin Ophthalmol; 2004; 19(1-2):1-12. PubMed ID: 15658006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema.
    Tunc M; Onder HI; Kaya M
    Ophthalmology; 2005 Jun; 112(6):1086-91. PubMed ID: 15885789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).
    Comyn O; Sivaprasad S; Peto T; Neveu MM; Holder GE; Xing W; Bunce CV; Patel PJ; Egan CA; Bainbridge JW; Hykin PG
    Am J Ophthalmol; 2014 May; 157(5):960-70. PubMed ID: 24531025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.
    Ahmadieh H; Ramezani A; Shoeibi N; Bijanzadeh B; Tabatabaei A; Azarmina M; Soheilian M; Keshavarzi G; Mohebbi MR
    Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):483-9. PubMed ID: 17917738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
    Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
    Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.